Time course of platelet reactivity in the acute phase of STEMI as measured with various platelet function studies

Time course of platelet reactivity in the acute phase of STEMI as measured with various platelet function studies - TOPS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38015

Enrollment

100

Registered

2011-04-12

Start date

2011-09-08

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Platelet reactivity

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient must meet ALL of the following criteria: • Males or females > 21 years of age and 1 mV in 2 adjacent ECG leads, with cumulative ST- segment deviation of 6 mm or more. • Patients should only be included if there is a reasonable expectation that PCI will be conducted within 1 hour.

Exclusion criteria

Exclusion criteria: 1) Patients who are unable to give informed consent or have life expectancy of

Design outcomes

Primary

Measure	Time frame
• Platelet function tests, including LTA, VerifyNow P2Y12, TEG, Multiplate, PFA (see appendix A) • Percentage platelet bound P-selectin expression (see appendix A) • Thrombin generation at high tissue factor concentration, at low tissue factor concentration and with microparticle reagens. • Coagulation factors: Full length tissue factor pathway inhibitor (FL-TFPI), total protein S, FVIII, vWF • Genetic variations associated with response to antiplatelet therapy and thrombus formation	—

Measure

Time frame

• Platelet function tests, including LTA, VerifyNow P2Y12, TEG, Multiplate, PFA (see appendix A) • Percentage platelet bound P-selectin expression (see appendix A) • Thrombin generation at high tissue factor concentration, at low tissue factor concentration and with microparticle reagens. • Coagulation factors: Full length tissue factor pathway inhibitor (FL-TFPI), total protein S, FVIII, vWF • Genetic variations associated with response to antiplatelet therapy and thrombus formation

—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results